Patient Raised Funds for International Cancer Care
A patient is seeking personalized immunotherapy options abroad following a primary brain tumour diagnosis.
Updated on Oct. 12, 2026 in Cancer
Raju has raised over £165,000 toward a £200,000 goal to access dendritic cell treatments and immunotherapy for a primary brain tumour. The fundraising efforts seek to provide care options outside of standard NHS protocols.
Why it matters
The patient initiated this effort because he believes options following standard NHS chemotherapy and radiotherapy for his brain tumour are currently limited. This highlights the challenges some patients face when navigating treatment options beyond established national care pathways.
This case reflects a fundraising initiative to secure access to immunotherapy and dendritic cell treatments abroad. Currently, these specific immunotherapy drugs are not approved as standard frontline treatments by NICE.
The players
NICE
The National Institute for Health and Care Excellence provides national guidance and standards for care in the NHS.
NHS
The National Health Service provides public medical care and standard oncology treatment pathways in the UK.
The details
Standard NHS care for primary brain tumours currently consists of a combination of surgery, radiotherapy, and chemotherapy. Raju is currently two weeks into a six-week course of chemotherapy and radiotherapy, which may be followed by six months of additional chemotherapy. The patient is exploring personalized immunotherapy and dendritic cell therapies in India, Germany, and the US as potential subsequent treatment options.
Timeline
Raju is currently two weeks into a six-week course of treatment.
The follow-up chemotherapy may last for an additional six months.
Health Landscape
The standard of care for primary brain tumours remains surgery, radiotherapy, and chemotherapy as defined by current national frameworks. This case underscores the ongoing gap between established care pathways and emerging, yet non-approved, personalized immunotherapy options.
Patients navigating complex cancer diagnoses should discuss all treatment pathways and clinical trial eligibility with their primary oncology team. Questions regarding the safety and scientific validation of international or non-approved therapies are important to raise with your doctor.
The takeaway
Understanding the distinction between standard-of-care treatments and experimental options is vital for oncology patients. Always consult with your medical team about the risks and scientific basis of any additional therapies being considered outside of your standard treatment plan.
Further reading
For more on the current standard of care and emerging research, visit our Cancer section.
Source note: This article includes information reported by BBC.
